Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

Company to Hold Conference Call on Monday, December 10, 2007

NEW HAVEN, Conn., Dec. 6 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that preliminary data from its pivotal Phase II trial of Cloretazine(R) (VNP40101M) in elderly patients with de novo acute myelogenous leukemia (AML) would be presented in a poster at the 2007 American Society of Hematology Annual Meeting in Atlanta, Georgia on Saturday, December 8, 2007.

The poster presentation (#71-1) will be at the Georgia World Conference Center, Hall B4, from 9:00 a.m. to 7:30 p.m. Poster authors will be available from 5:30 p.m. to 7:30 p.m. at the poster. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on Saturday, December 8, 2007 at 9:00 a.m. Eastern Time.

A press release related to the poster will be issued on Monday, December 10, 2007 at 7:30 a.m. Eastern Time. The Company also announced that it would hold a conference call to discuss the poster on Monday, December 10, 2007. The call will begin at 9:00 a.m. Eastern Time.

To participate in the conference call, please dial (866) 356-4123 in the U.S. ((617) 597-5393 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 16444471.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to a
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ... research report to its store . ... from aging of population, consumption upgrade and policy ... industry has seen rapid development over the years, ... yuan in 2006 to 9.85 billion yuan in ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of ... helping those in need; so to support these emergency ... contributions up to $250,000, which could mean up to ... through AARP Foundation. (Logo: http://photos.prnewswire.com/prnh/20070209/NYF043LOGO ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Office of Fair Trading (OFT) approval condition to the announced ... Incorporated (NASDAQ: VPHM).   As a result of ... approval, and Shire expects to complete the tender offer on ... to the satisfaction of all of the remaining conditions to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Nov. 14 The following is,the prepared testimony of ... and Drug Administration (FDA) regarding behind the counter,availability of ... of the National Community,Pharmacists Association (NCPA) and a pharmacist ... thank the FDA for holding this public meeting to,explore ...
... CHAPEL HILL, N.C., Nov. 14 Research that ... new product,launches to manufacturing and online financial services ... an online research repository managed by,research and consulting ... key findings and key metrics in these studies, ...
... The finding might help lead to new treatments, scientists say ... they,ve have uncovered a biological "switch" for key genes in ... are silenced by distinct changes in the density of structures ... the first time exactly how genes get shut down in ...
... has indicated that FlexNow(R) Joint Formula shows significant, ... pain., EGG HARBOR TWP., N.J., Nov. 14 ... FlexNow(R) Joint Formula, has announced the,findings from the ... June,at the Australian Centre for Complementary Medicine Education ...
... from Peripheral Arterial Disease is Caused,by Smoking, ... well,aware of the risk of cancer from smoking, ... body,s vascular system. Smoking damages the,blood vessels and ... including,peripheral arterial disease (PAD), stroke, heart attack, abdominal ...
... 14 Following is a statement,by Linda A. ... (CHPA), regarding today,s FDA public meeting seeking comments,on ... behalf of our member companies, CHPA was pleased ... discussion of expanded consumer,access to medicines. As the ...
Cached Medicine News:Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 2Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 3Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 4Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 5Health News:Best Practice Database Adds New Research on New Product Launches, Online Financial Services and Manufacturing Operations 2Health News:Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study 2Health News:A New Reason to Quit for the Great American Smokeout 2Health News:Statement From the Consumer Healthcare Products Association on Proposed New 'Third Class' of Medicines 2
... onboard rail clamps mount ... tables and stretchers. The ... need for lifting. Easy ... stable surface combined with ...
The DHS Basic Set is available with either self-tapping or non-self-tapping screws. Either instrument set provides complete instrumentation in one graphic case for use with the Universal Implant Set,...
... is a versatile, fully powered orthopaedic and ... traction facilities, a powered centre break and ... versatile too. ,<br.,In fact the RX600 is ... it is for traction procedures. The RX600 ...
... orthopedic trauma procedures. Part of the ... trauma table top provides a complete, ... positioning and provides for skin or ... hip pinnings; femur, supine or lateral ...
Medicine Products: